All In Biotech

Drug Trial Radar · NCT05987332

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Oct 31, 2023

Primary completion

Jan 15, 2027

Study completion Jan 15, 2028

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator's choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Conditions

  • Metastatic Uveal Melanoma

Interventions

  • IDE196Drug

    Dosed orally, twice daily

  • CrizotinibDrug

    Dosed orally, twice daily

  • PembrolizumabDrug

    IV administration every 3 weeks

  • IpilimumabDrug

    IV administration every 3 weeks for 4 Cycles

  • NivolumabDrug

    IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance

  • DacarbazineDrug

    IV administration every 3 Weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following:Time frame: Approximately 5 months
  2. Phase 2 Progression-Free Survival (PFS)Time frame: Approximately 2 years
  3. Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment.Time frame: Approximately 4 years

Locations

68 sites in 13 countries. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona

  • Moores Cancer Center

    La Jolla, California

  • UCLA Medical Center

    Los Angeles, California

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • California Pacific Medical Center (CPMC)

    San Francisco, California

  • University of California San Francisco

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • SCRI at HealthONE

    Denver, Colorado

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Northside Hospital Atlanta

    Atlanta, Georgia

  • University of Iowa

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan

  • Minnesota Oncology Hematology, P.A.

    Burnsville, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Northwell Health

    Manhasset, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Duke University Health System

    Durham, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology- DFW

    Dallas, Texas

  • UT Southwestern Medical Center

    Dallas, Texas

  • Houston Methodist Cancer Center

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Queen Elizabeth Hospital

    Adelaide, Australia

  • Westmead Hospital

    Sydney, New South Wales, Australia

  • Princess Alexander Hospital

    Brisbane, Queensland, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Alfred Health

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Perth, Washington, Australia

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • Algemene Medische Oncologie UZ

    Leuven, Belgium

  • Cross Cancer Institute, University of Alberta

    Edmonton, Alberta, Canada

Showing 40 of 68 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.